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Among chronic diabetic complications, diabetic peripheral 
polyneuropathy (DPN) is characterized by a progressive natu-
ral course and severe symptoms. The reported prevalence of 
DPN varies dramatically depending on differences in diagnos-
tic methods, patient selection, and definition of neuropathy 
from 8.3% for patients with newly diagnosed type 2 diabetes to 
up to 50% in patients who have had diabetes for 25 years [1,2]. 
DPN is often subclinical. Up to 50% of DPN cases may be as-
ymptomatic, and such patients are at risk of insensate injury to 
their feet. DPN is an important risk factor for foot ulceration, 
lower limb amputation, and mortality [3,4].
  Recently reported observational and epidemiologic studies 
have shown that the clinical significance of DPN is not con-
fined to the prevention of diabetic foot problems. Relationships 
have been demonstrated between DPN and other diabetic mi-
crovascular complications. Close associations among diabetic 
nephropathy, retinopathy, and neuropathy have been reported 
by many studies, both in patients with type 1 and type 2 diabe-
tes mellitus. The EURODIAB Prospective Complication Study 
showed that diabetic nephropathy and retinopathy were both 
associated with low nerve conduction velocity and amplitude 
response in type 1 diabetes [5]. According to a population-
based study of type 2 diabetes performed in Sweden, periph-
eral sensory neuropathy was related to diabetic retinopathy, 
overt nephropathy, and peripheral vascular disease [6]. 
  Among diabetic neuropathies, cardiovascular autonomic 
neuropathy (CAN) is widely accepted as an independent risk 
factor for future adverse cardiovascular outcomes such as si-
lent myocardial ischemia, cardiac arrhythmia or sudden death 
[7]. CAN is common in patients with diabetes and is associat-
ed with modifiable factors including central fat distribution, 
hypertension, dyslipidemia, poor diabetes control, and smok-
ing, and with other microvascular complications of diabetes 
[8]. However, the relationships between DPN and cardiovas-
cular disease (CVD) outcomes in patients with type 2 diabetes 
have not been fully investigated.
  Due to a lack of large prospective long-term epidemiologic 
studies of DPN and cardiovascular or cerebrovascular disease, 
clinical evidence of their relationships are limited. The EURO-
DIAB Prospective Complications Study included 1,407 patients 
with type 1 diabetes and showed that cardiovascular risk fac-
tors such as male sex, hypertension, obesity, dyslipidemia, and 
smoking predict the development of large-fiber dysfunction, 
as measured by vibration perception threshold [9]. Previous 
clinical history of cardiovascular disease increased the incidence 
of large-fiber dysfunction with an odds ratio (OR) of 2.13. Cop-
pini et al. [4] showed that higher vibration perception thresh-
olds were more strongly associated with increased mortality 
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  Owolabi et al. [10] showed that aggregate cardiovascular risk 
load, which was determined using the UK Prospective Diabe-
tes Study risk engines, was more strongly correlated with and a 
predictor of clinically evident diabetic peripheral neuropathy 
than was hemoglobin A1c (HbA1c). In addition, Jarmuzewska 
et al. [11] demonstrated an independent association between 
pulse pressure and hypertension and diabetic peripheral neu-
ropathy in patients with type 2 diabetes. In The Detection of 
Ischemia in Asymptomatic Diabetics (DIAD) study, which was 
a prospective randomized controlled trial in which participants 
were randomized either to be systematically screened with 
stress myocardial perfusion imaging or not to be screened, re-
lationships were detected between development of CVD and 
symptoms of peripheral neuropathy (numbness and pain) or 
diminished peripheral sensation in type 2 diabetic patients [12]. 
  Contrary to the relationship between DPN and cardiovas-
cular risk factors or CVD in subjects with type 2 diabetes, the 
EURODIAB Prospective Complication Study of type 1 diabe-
tes demonstrated a close relationship between the presence of 
microvascular complications and reduced peripheral nerve 
conduction velocity and amplitude. However, no associations 
between cardiovascular disease and nerve conduction study 
findings were observed [5]. 
  In the present cross-sectional study, Chung et al. investigat-
ed the relationships between DPN and cardiovascular compli-
cations in Korean type 2 diabetic patients. The mean age of the 
participants was 62.2 years, and all patients had long-standing 
type 2 diabetes (mean diabetic duration, 12.2 years). The au-
thors assessed the presence of peripheral neuropathy using 
sensory and motor nerve conduction studies in a large study 
sample (n=1,041), and the prevalence of DPN was 52.8%. Al-
though nerve conduction studies (NCS) are considered the 
gold standard for assessing nerve damage and the most con-
sistent indicator of neuropathy [13], NCS are generally not 
available or recommended as routine screening for the diag-
nosis of diabetic neuropathy. According to clinical practice 
guidelines, electrophysiological testing is rarely needed except 
when clinical features are atypical [14,15]. However, Chung et 
al. performed NCV in this large sample, and provided valuable 
information about NCV abnormalities in type 2 diabetic pa-
tients with peripheral neuropathy. Consistent with previous 
reports, the prevalences of diabetic retinopathy, nephropathy, 
or autonomic neuropathy were higher in patients with DPN, 
remaining significant after adjustment for age, diabetes dura-
tion, and hypertension. Importantly, diabetic polyneuropathy 
was more prevalent in patients with clinical history with CVD, 
based on NCS findings. In addition, diabetic polyneuropathy 
was independently associated with presence of CVD in type 2 
diabetic patients (OR, 1.801). 
  The pathogenic mechanism or causal relationship between 
CVD and diabetic peripheral neuropathy was not clarified. As 
the authors suggested, distal symmetrical neuropathy might 
be associated with medial arterial calcification in diabetes mel-
litus patients. In addition, patients with long-standing diabetes 
develop not only microvascular complications, including pe-
ripheral neuropathy, but also cardiovascular autonomic neu-
ropathy. Moreover, metabolic abnormalities related to cardio-
vascular risk factors might coexist and influence each other. A 
prospective, long-term cohort study should be conducted in 
the future. 
  Regardless of pathogenesis, like other microvascular com-
plications, diabetic polyneuropathy may be prevented by in-
tensive glycemic control. The recently published ACCORD 
study found that intensive glycemic control delayed the onset 
of diabetic microvascular complications, including neuropa-
thy [16]. Most importantly, somatic and autonomic dysfunc-
tion are significant risk factors for CVD, and therefore the 
presence of peripheral and cardiovascular autonomic neurop-
athy should be actively screened at the time of diagnosis of di-
abetes and aggressively treated in patients with type 2 diabetes. 
We appreciate the efforts of Chung et al., who provide impor-
tant information about diabetic polyneuropathy and cardio-
vascular risk factors for CVD in Korean patients with type 2 
diabetes. 
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